Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 1/2020

Open Access 01-01-2020 | Metastasis | Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer

Authors: Adrian Szczepaniak, Jakub Fichna, PhD, DSc, Marta Zielińska, PhD

Published in: Current Treatment Options in Oncology | Issue 1/2020

Login to get access

Opinion statement

So far, opioids have been successfully used to reduce cancer pain in patients in order to improve their quality of life. However, the use of opioids leads to numerous side effects such as constipation, drowsiness, nausea, itching, increased sweating and hormonal changes. In this review, we described the action of opioids in several molecular pathways significant for maintenance of the intestinal homeostasis including the impact on the intestinal epithelium integrity, changes in microbiome composition, modulation of the immune system or induction of apoptosis and inhibition of angiogenesis. We summed up the role of individual opioids in the processes involved in the growth and development of cancer and elucidated if targeting opioid receptors may constitute novel therapeutic option in colon cancer.
Literature
1.
• Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–48 It is a comprehensive analysis (performed using Global Burden of Disease methodology) of mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life-years for 32 cancers in 195 countries and territories from 1990 to 2015.
2.
3.
4.
Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B, et al. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 2013:232–50.PubMed
5.
Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002;38(3):351–76.PubMed
6.
Gach K, Szemraj J, Stasikowska-Kanicka O, Danilewicz M, Janecka A. Opioid-receptor gene expression and localization in cancer cells. Open Life Sci. 2011;6(1):10–5.
7.
• Boland JW, McWilliams K, Ahmedzai SH, Pockley AG. Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. Br J Cancer. 2014:866–73 This interesting review summed up a knowledge about impact of different opioids on anti-tumour immunity and it can be found how difficult is to manage with drug therapy using opioids in patients with cancer.PubMedPubMedCentral
8.
Maneckjee R. Anticancer effects of therapeutic opioids. Pain Forum. 1999;8(4):213–5.
9.
Akbari M, Naghibzadeh-Tahami A, Khanjani N, Baneshi MR, Kamali E, Hesampour M, et al. Opium as a risk factor for bladder cancer: a population-based case-control study in Iran. Arch Iran Med. 2015;18(9):567–71.PubMed
10.
Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455–61.PubMed
11.
Razmpa E, Saedi B, Motiee-Langroudi M, Garajei A, Hoseinpor S, Motamedi MHK. Opium usage as an etiologic factor of oral cavity cancer. J Craniofac Surg. 2014;25(5):e505–7.PubMed
12.
Shakeri R, Kamangar F, Nasrollahzadeh D, Nouraie M, Khademi H, Etemadi A, et al. Is opium a real risk factor for esophageal cancer or just a methodological artifact? hospital and neighborhood controls in case-control studies. PLoS One. 2012;7(3):e32711.PubMedPubMedCentral
13.
Frenklakh L, Bhat RS, Bhaskaran M, Sharma S, Sharma M, Dinda A, et al. Morphine-induced degradation of the host defense barrier. Dig Dis Sci. 2006;51(2):318–25.PubMed
14.
Harari Y, Weisbrodt NW, Moody FG. The effect of morphine on mast cell-mediated mucosal permeability. Surgery. 2006;139(1):54–60.PubMed
15.
16.
Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract. 2001;197(10):683–9.PubMed
17.
• Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8) An interesting review on the intestinal epithelial barrier.
18.
Wang F, Roy S. Gut homeostasis, microbial dysbiosis, and opioids. Toxicol Pathol. 2017;45(1):150–6.PubMed
19.
Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Fernandez SF, et al. Tight junction regulation by morphine and HIV-1 tat modulates blood–brain barrier permeability. J Clin Immunol. 2008;28(5):528–41.PubMed
20.
Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R, et al. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. Buch SJ, editor. PLoS One. 2013;8(1):e54040.PubMedPubMedCentral
21.
•• Bauman BD, Meng J, Zhang L, Louiselle A, Zheng E, Banerjee S, et al. Enteric glial-mediated enhancement of intestinal barrier integrity is compromised by morphine. J Surg Res. 2017;219:214–21 An important involvement of the maintenance of intestinal epithelium integrity.PubMedPubMedCentral
22.
Okura T, Ozawa T, Ibe M, Taki Y, Kimura M, Kagawa Y, et al. Effects of repeated morphine treatment on the antinociceptive effects, intestinal absorption, and efflux from intestinal epithelial cells of morphine. Biol Pharm Bull. 2009;32(9):1571–5.PubMed
23.
•• Wang F, Meng J, Zhang L, Johnson T, Chen C, Roy S. Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. Sci Rep. 2018;8(1):3596 In this paper authors indicated that morphine induced distinct alterations in the gut microbiome and metabolome, contributed to negative consequences combined with opioid administration.PubMedPubMedCentral
24.
de Almeida CV, Taddei A, Amedei A. The controversial role of enterococcus faecalis in colorectal cancer. Ther Adv Gastroenterol. 2018;11:1756284818783606.
25.
Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis. 2002;23(3):529–36.PubMed
26.
Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105(24):1907–11.PubMedPubMedCentral
27.
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306.PubMedPubMedCentral
28.
Greiner T, Bäckhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab. 2011;22(4):117–23.PubMed
29.
30.
Liang X, Liu R, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review. Transl Perioper Pain Med. 2016;1(1):5–13.PubMedPubMedCentral
31.
Baldini A, Von Korff M, Lin EHB. A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. Prim Care Companion CNS Disord. 2012;14(3).
32.
Chan Y-Y, Yang S-N, Lin J-C, Chang J-L, Lin J-G, Lo W-Y. Inflammatory response in heroin addicts undergoing methadone maintenance treatment. Psychiatry Res. 2015;226(1):230–4.PubMed
33.
• Fakhraei N, Javadian N, Rahimian R, Nili F, Rahimi N, Hashemizadeh S, et al. Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats. Inflammopharmacology. 2018;26(6):1399–413 In this study it was found that methadone may induce anti-inflammatory action during colonic inflammation through opioid receptors located mainly in the central nervous system.PubMed
34.
Du J-Y, Liang Y, Fang J-F, Jiang Y-L, Shao X-M, He X-F, et al. Effect of systemic injection of heterogenous and homogenous opioids on peripheral cellular immune response in rats with bone cancer pain: a comparative study. Exp Ther Med. 2016;12(4):2568–76.PubMedPubMedCentral
35.
Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, et al. Differences in δ- and μ-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33(3):653–65.PubMed
36.
Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.PubMedPubMedCentral
37.
Yi Z, Guo S, Hu X, Wang X, Zhang X, Griffin N, et al. Functional modulation on macrophage by low dose naltrexone (LDN). Int Immunopharmacol. 2016;39:397–402.PubMed
38.
Kajihara M, Takakura K, Kanai T, Ito Z, Saito K, Takami S, et al. Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol. 2016;22(17):4275–86.PubMedPubMedCentral
39.
Liu J, Chen W, Meng J, Lu C, Wang E, Shan F, et al. Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK). Cancer Immunol Immunother. 2012;61(10):1699–711.PubMed
40.
Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg. 1996;82(3):492–7.PubMed
41.
Yeager MP, Procopio MA, DeLeo JA, Arruda JL, Hildebrandt L, Howell AL. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesth Analg. 2002;94(1):94–9.PubMed
42.
Odunayo A, Dodam JR, Kerl ME, DeClue AE. Immunomodulatory effects of opioids. J Vet Emerg Crit Care. 2010.
43.
Palm S, Lehzen S, Mignat C, Steinmann J, Leimenstoll G, Maier C. Does prolonged oral treatment with sustained-release morphine tablets influence immune function? Anesth Analg. 1998;86(1):166–72.PubMed
44.
Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J, et al. Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. Anticancer Res. 2011;31(12):4561–8.PubMed
45.
Suzuki M, Sakurada T, Gotoh K, Watanabe S, Satoh N. Correlation between the administration of morphine or oxycodone and the development of infections in patients with cancer pain. Am J Hosp Palliat Med. 2013;30(7):712–6.
46.
Molina-Martínez LM, González-Espinosa C, Cruz SL. Dissociation of immunosuppressive and nociceptive effects of fentanyl, but not morphine, after repeated administration in mice: fentanyl-induced sensitization to LPS. Brain Behav Immun. 2014;42:60–4.PubMed
47.
Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus–pituitary–adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun. 2007;21(6):767–74.PubMed
48.
Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Neuroimmunomodulation. 2004;11(4):255–60.PubMed
49.
Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16(6):2129–44.PubMed
50.
Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590–607.PubMed
51.
Tian M, Jin L, Li R, Zhu S, Ji M, Li W. Comparison of oxycodone and morphine on the proliferation, apoptosis and expression of related molecules in the A549 human lung adenocarcinoma cell line. Exp Ther Med. 2016;12(2):559–66.PubMedPubMedCentral
52.
Xu YJ, Li SY, Cheng Q, Chen WK, Wang SL, Ren Y, et al. Effects of anaesthesia on proliferation, invasion and apoptosis of LoVo colon cancer cells in vitro. Anaesthesia. 2016;71(2):147–54.PubMed
53.
Tegeder I, Grösch S, Schmidtko A, Häussler A, Schmidt H, Niederberger E, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63(8):1846–52.PubMed
54.
Zagon IS, McLaughlin PJ. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 2003;37(2):79–88.PubMed
55.
Kocak N, Ozen F, Yildirim IH, Duran Y. Fentanyl inhibits tumorigenesis from human breast stem cells by inducing apoptosis. Asian Pac J Cancer Prev. 2017;18(3):735–9.PubMedPubMedCentral
56.
Özgürbüz U, Gencür S, Kurt FÖ, Özkalkanlı M, Vatansever HS. The effects of tramadol on cancer stem cells and metabolic changes in colon carcinoma cells lines. Gene. 2019;718:144030.PubMed
57.
Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, et al. Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018;11:2063–73.PubMedPubMedCentral
58.
59.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed
60.
Borner C, Kraus J. Inhibition of NF- B by opioids in T cells. J Immunol. 2013;191(9):4640–7.PubMed
61.
Qiu S, Feng Y, LeSage G, Zhang Y, Stuart C, He L, et al. Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating P65 and TRAF6. J Immunol. 2015;194(3):1021–30.PubMed
62.
Borner C, Hollt V, Kraus J. Mechanisms of the inhibition of nuclear factor- B by morphine in neuronal cells. Mol Pharmacol. 2012;81(4):587–97.PubMed
63.
Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, et al. Morphine inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology. 2000;92(6):1677–84.PubMed
64.
Beltran JA, Peek J, Chang SL. Expression and regulation of the mu opioid peptide receptor in TPA-differentiated HL-60 promyelocytic leukemia cells. Int Immunopharmacol. 2006;6(8):1331–40.PubMed
65.
Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62(2):233–44.PubMed
66.
Capasso A. The effect of morphine on the expression of COX-2 and iNOS enzymes. Cent Nerv Syst Agents Med Chem. 2008;8(1):1–9.
67.
Waldman SA, Terzic A. A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer. FEBS J. 2009;276(8):2157–64.PubMedPubMedCentral
68.
Zhou T, Zhang G, Liu Z, Xia S, Tian H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Color Dis. 2013;28(1):19–24.
69.
Kong W-Q, Bai R, Liu T, Cai C-L, Liu M, Li X, et al. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J. 2012;279(7):1252–60.PubMed
70.
Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012;228(2):204–15.PubMed
71.
Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15(6):546–54.PubMedPubMedCentral
72.
Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60(1):167–79.PubMed
73.
Zhang XL, Chen ML, Zhou SL. Fentanyl inhibits proliferation and invasion of colorectal cancer via β-catenin. Int J Clin Exp Pathol. 2015;8(1):227–35.PubMedPubMedCentral
74.
Liu H, Du L, Wen Z, Yang Y, Li J, Wang L, et al. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Color Dis. 2013;28(5):697–703.
75.
Wang N, Zhang Z, Lv J. Fentanyl inhibits proliferation and invasion via enhancing miR-302b expression in esophageal squamous cell carcinoma. Oncol Lett. 2018;16(1):459–66.PubMedPubMedCentral
76.
Blebea J, Mazo JE, Kihara TK, Vu J-H, McLaughlin PJ, Atnip RG, et al. Opioid growth factor modulates angiogenesis. J Vasc Surg. 2000;32(2):364–73.PubMed
77.
Dai X, Cui S, Wang T, Liu Q, Song H, Wang R. Endogenous opioid peptides, endomorphin-1 and -2 and deltorphin I, stimulate angiogenesis in the CAM assay. Eur J Pharmacol. 2008;579(1–3):269–75.PubMed
78.
• Yamamizu K, Hamada Y, Narita M. κ Opioid receptor ligands regulate angiogenesis in development and in tumours. Br J Pharmacol. 2015;172(2):268–76 In this study it was found that methadone may induce anti-inflammatory action during colonic inflammation through opioid receptors located mainly in the central nervous system.PubMed
79.
Ondrovics M, Hoelbl-Kovacic A, Fux DA. Opioids: modulators of angiogenesis in wound healing and cancer. Oncotarget. 2017;8(15):25783–96.PubMedPubMedCentral
80.
Nguyen J, Luk K, Vang D, Soto W, Vincent L, Robiner S, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014;113(Suppl 1):i4–13.PubMedPubMedCentral
81.
Koodie L, Ramakrishnan S, Roy S. Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol. 2010;177(2):984–97.PubMedPubMedCentral
82.
Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62(15):4491–8.PubMed
83.
Martin JL, Charboneau R, Barke RA, Roy S. Chronic morphine treatment inhibits LPS-induced angiogenesis: implications in wound healing. Cell Immunol. 2010;265(2):139–45.PubMedPubMedCentral
84.
Moradi M, Esmaeili S, Shoar S, Safari S. Use of oxycodone in pain management. Anesthesiol Pain Med. 2012;1(4):262–4.
85.
Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta Rev Cancer. 2009:293–308.
86.
Fagan-Solis KD, Schneider SS, Pentecost BT, Bentley BA, Otis CN, Gierthy JF, et al. The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem. 2013;114(6):1385–94.PubMed
87.
Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol. 2003:465–70.PubMed
88.
Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187(1–2):121–7.PubMed
89.
Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, Delbro DS. Functional expression of μ-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig Dis Sci. 2008;53(2):461–6.PubMed
90.
• Khabbazi S, Hassanshahi M, Hassanshahi A, Peymanfar Y, Su Y-W, Xian CJ. Opioids and matrix metalloproteinases: the influence of morphine on MMP-9 production and cancer progression. Naunyn Schmiedeberg's Arch Pharmacol. 2019;392(2):123–33 In this review possible influence of opioids such as morphine on matrix metalloproteinases production through different molecular pathways has been discussed.
91.
Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer. 2003;107(4):541–50.PubMed
92.
Cata JP, Keerty V, Keerty D, Feng L, Norman PH, Gottumukkala V, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900–8.PubMedPubMedCentral
93.
Hasegawa T, Oguri T, Osawa T, Sawa T, Osaga S, Okuyama T, et al. Opioid dose and survival of patients with incurable nonsmall cell lung cancer: a prospective cohort study. J Palliat Med. 2018;21(10):1436–41.PubMed
94.
Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(11):2032–8.
95.
Sathornviriyapong A, Nagaviroj K, Anothaisintawee T. The association between different opioid doses and the survival of advanced cancer patients receiving palliative care. BMC Palliat Care. 2016;15(1):95.PubMedPubMedCentral
96.
Sessler DI, Pei L, Huang Y, Fleischmann E, Marhofer P, Kurz A, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet. 2019;394(10211):1807–15.PubMed
97.
Sekandarzad MW, Doornebal C, Hollmann MW. Opiophobia in cancer biology- justified? - the role of perioperative use of opioids in cancer recurrence. Curr Pharm Des. 2019;25(28):3020–7.PubMed
98.
Cao L-H, Li H-T, Lin W-Q, Tan H-Y, Xie L, Zhong Z-J, et al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016;6:18706.PubMedPubMedCentral
99.
He B, Tong X, Wang L, Wang Q, Ye H, Liu B, et al. Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Clin Cancer Res. 2009;15(18):5803–10.PubMed
Metadata
Title
Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer
Authors
Adrian Szczepaniak
Jakub Fichna, PhD, DSc
Marta Zielińska, PhD
Publication date
01-01-2020
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 1/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-019-0699-1

Other articles of this Issue 1/2020

Current Treatment Options in Oncology 1/2020 Go to the issue

Skin Cancer (T Ito, Section Editor)

Epidermal Growth Factor Receptor’s Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies

Leukemia (PH Wiernik, Section Editor)

Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy

Palliative and Supportive Care (MP Davis, Section Editor)

Prognosticating for Adult Patients With Advanced Incurable Cancer: a Needed Oncologist Skill

Leukemia (PH Wiernik, Section Editor)

The Microbiota in Hematologic Malignancies

Head and Neck Cancer (CP Rodriguez, Section Editor)

Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment

Leukemia (PH Wiernik, Section Editor)

Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits